Mashhad University of Medical Sciences in collaboration with
AOFNMBAsia Oceania Journal of Nuclear Medicine and Biology2322-57185120170101Whole-Body Distribution of Donepezil as an Acetylcholinesterase Inhibitor after Oral Administration in Normal Human Subjects: A 11C-donepezil PET Study39751310.22038/aojnmb.2016.7513ENIkuko MochidaDepartment of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine
Osaka University Graduate School of Medicine Immunology Frontier Research CenterEku ShimosegawaDepartment of Molcular Imaging in Medicine, Osaka University Graduate School of Medicine
Department of Molcular Imaging in Medicine, Osaka University Graduate School of MedicineYasukazu KanaiDepartment of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine
Department of Molcular Imaging in Medicine, Osaka University Graduate School of MedicineSadahiro NakaDepartment of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine
Osaka University HospitalJun HatazawaDepartment of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine
Osaka University Graduate School of Medicine Immunology Frontier Research CenterKeiko MatsunagaDepartment of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine
Osaka University Graduate School of Medicine Immunology Frontier Research CenterKayako IsohashiDepartment of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine
Department of Molcular Imaging in Medicine, Osaka University Graduate School of MedicineGenki HoritsugiDepartment of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of MedicineTadashi WatabeDepartment of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine
Department of Molcular Imaging in Medicine, Osaka University Graduate School of Medicine0000-0001-8658-2395Hiroki KatoDepartment of Nuclear Medicine and Tra
cer Kinetics, Osaka University Graduate School of Medicine
Department of Molcular Imaging in Medicine, Osaka University Graduate School of MedicineJournal Article20160329Objective(s): It is difficult to investigate the whole-body distribution of an orally administered drug by means of positron emission tomography (PET), owing to the short physical half-life of radionuclides, especially when 11C-labeled compounds are tested. Therefore, we aimed to examine the whole-body distribution of donepezil (DNP) as an acetylcholinesterase inhibitor by means of 11C-DNP PET imaging, combined with the oral administration of pharmacological doses of DNP.<br />Methods: We studied 14 healthy volunteers, divided into group A (n=4) and group B (n=10). At first, we studied four females (mean age: 57.3±4.5 y), three of whom underwent 11C-DNP PET scan at 2.5 h after the oral administration of 1 mg and 30 μg of DNP, respectively, while one patient was scanned following the oral administration of 30 μg of DNP (group A). Then, we studied five females and five males (48.3±6.1 y), who underwent 11C-DNP PET scan, without the oral administration of DNP (group B). Plasma DNP concentration upon scanning was measured by tandem mass spectrometry. Arterialized venous blood samples were collected periodically to measure plasma radioactivity and metabolites. In group A, 11C-DNP PET scan of the brain and whole body continued for 60 and 20 min, respectively. Subjects in group B underwent sequential whole-body scan for 60 min. The regional uptake of 11C-DNP was analyzed by measuring the standard uptake value (SUV) through setting regions of interest on major organs with reference CT.<br />Results: In group A, plasma DNP concentration was significantly correlated with the orally administered dose of DNP. The mean plasma concentration was 2.00 nM (n=3) after 1 mg oral administration and 0.06 nM (n=4) after 30 μg oral administration. No significant difference in plasma radioactivity or fraction of metabolites was found between groups A and B. High 11C-DNP accumulation was found in the liver, stomach, pancreas, brain, salivary glands, bone marrow, and myocardium in groups A and B, in this order. No significant difference in SUV value was found among 11C-DNP PET studies after the oral administration of 1 mg of DNP, 30 μg of DNP, or no DNP.<br />Conclusion: The present study demonstrated that the whole-body distribution of DNP after the oral administration of pharmacological doses could be evaluated by 11C-DNP PET studies, combined with the oral administration of DNP.Mashhad University of Medical Sciences in collaboration with
AOFNMBAsia Oceania Journal of Nuclear Medicine and Biology2322-57185120170101Diagnostic Performance and Safety of Positron Emission Tomography Using 18F-Fluciclovine in Patients with Clinically Suspected High- or Low-grade Gliomas: A Multicenter Phase IIb Trial1021786910.22038/aojnmb.2016.7869ENToshihiko WakabayashiDepartment of Neurosurgery, Nagoya University, Graduate School of MedicineToshihiko IuchiDivision of Neurological Surgery, Chiba Cancer CenterNaohiro TsuyuguchiDepartment of Neurosurgery, Osaka City University Graduate School of MedicineRyo NishikawaDepartment of Neuro-Oncology/Neurosurgery, Saitama International Medical Center, Saitama Medical UniversityYoshiki ArakawaDepartment of Neurosurgery, Kyoto University Graduate School of MedicineTakashi SasayamaDepartment of Neurosurgery, Kobe University Graduate School of MedicineKeisuke MiyakeDepartment of Neurological Surgery, Faculty of Medicine, Kagawa UniversityTadashi NariaiDepartment of Neurosurgery, Tokyo Medical and Dental UniversityYoshitaka NaritaDepartment of Neurosurgery and Neuro-Oncology, National Cancer Center HospitalNaoya HashimotoDepartment of Neurosurgery, Osaka University Graduate School of MedicineOsamu OkudaDepartment of Neurosurgery, Juntendo Tokyo Koto Geriatric Medical CenterHiroshi MatsudaIntegrative Brain Imaging Center, National Center of Neurology and Psychiatry0000-0002-6297-9897Kazuo KubotaDivision of Nuclear Medicine,
Department of Radiology, National Center for Global Health and MedicineKimiteru ItoDepartment of Radiology, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology0000-0003-0905-6767Yoichi NakazatoDepartment of Pathology, Hidaka HospitalKan KubomuraClinical Development Department, Nihon Medi-Physics Co., Ltd.Journal Article20160707Objective(s): The study objective was to assess the diagnostic performance of positron emission tomography (PET) for gliomas using the novel tracer 18F-fluciclovine (anti-[18F]FACBC) and to evaluate the safety of this tracer in patients with clinically suspected gliomas.<br />Methods: Anti-[18F]FACBC was administered to 40 patients with clinically suspected high- or low-grade gliomas, followed by PET imaging. T1-weighted, contrast-enhanced T1-weighted, and fluid-attenuated inversion recovery (or T2-weighted) magnetic resonance imaging (MRI) scans were obtained to plan for the tissue collection. Tissues were collected from either “areas visualized using anti-[18F]FACBC PET imaging but not using contrast-enhanced T1-weighted imaging” or “areas visualized using both anti-[18F]FACBC-PET imaging and contrast-enhanced T1-weighted imaging” and were histopathologically examined to assess the diagnostic accuracy of anti-[18F]FACBC-PET for gliomas.<br />Results: The positive predictive value of anti-[18F]FACBC-PET imaging for glioma in areas visualized using anti-[18F]FACBC-PET imaging, but not visualized using contrast-enhanced T1- weighted images, was 100.0% (26/26), and the value in areas visualized using both contrastenhanced T1-weighted imaging and anti- [18F]FACBC-PET imaging was 87.5% (7/8). Twelve adverse events occurred in 7 (17.5%) of the 40 patients who received anti-[18F]FACBC. Five events in five patients were considered to be adverse drug reactions; however, none of the events were serious, and all except one resolved spontaneously without treatment.<br />Conclusion: This Phase IIb trial showed that anti-[18F]FACBC-PET imaging was effective for the detection of gliomas in areas not visualized using contrast-enhanced T1-weighted MRI and the tracer was well tolerated.Mashhad University of Medical Sciences in collaboration with
AOFNMBAsia Oceania Journal of Nuclear Medicine and Biology2322-57185120170101Assessment of mediastinal tumors using SUVmax and volumetric parameters on FDG PET/CT2229799610.22038/aojnmb.2016.7996ENTakahiro MoritaDepartment of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of MedicineMitsuaki TatsumiDepartment of Radiology, Osaka University Hospital0000-0000-0000-0000Mana IshibashiDepartment of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of MedicineKayako IsohashiDepartment of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of MedicineHiroki KatoDepartment of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of MedicineOsamu HondaDepartment of Radiology, Osaka University Graduate School of MedicineEku ShimosegawaDepartment of Molecular Imaging in Medicine, Osaka University Graduate School of MedicineNoriyuki TomiyamaDepartment of Radiology, Osaka University Graduate School of MedicineJun HatazawaDepartment of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of MedicineJournal Article20160804Objective(s): This study aimed to evaluate the role of pretreatment SUVmax and volumetric FDG positron emission tomography (PET) parameters in the differentiation between benign and malignant mediastinal tumors. In addition, we investigated whether pretreatment SUVmax and volumetric FDG-PET parameters could distinguish thymomas from thymic carcinomas, and low-risk from high-risk thymomas.<br />Methods: This study was conducted on 52 patients with mediastinal tumors undergoing FDG-PET/CT. Histological examination indicated that 29 mediastinal tumors were benign, and 23 cases were malignant. To obtain quantitative PET/CT parameters, we determined the maximum standardized uptake value (SUVmax), volumetric parameters, metabolic tumor volume (MTV), and total lesion glycolysis (TLG) for primary tumors using SUVmax cut-off value of 2.5. SUVmax, MTV and TLG of benign and malignant tumors were compared<br />using the Mann-Whitney U test. Moreover, receiver-operating curve (ROC) analysis was applied to identify the cut-off values of SUVmax, MTV and TLG for the accurate differentiation of benign and malignant tumors. SUVmax, MTV and TLG were compared between thymomas and thymic carcinomas, as well as low-risk and high-risk thymomas.<br />Results: Mean SUVmax, MTV and TLG of malignant mediastinal tumors were significantly higher compared to benign tumors (P<0.001). Sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of SUVmax were 78.2%, 86.2%, 82.6%,81.8%, and 83.3%, respectively. These values were estimated at 82.6%, 96.6%, 90.4%,95%, and 87.5% for MTV and TLG, respectively. Additionally, optimal cut-off values for the differentiation of benign and malignant mediastinal tumors were determined at 4.2 and 22.3 mL and 79.7 g for SUVmax, MTV and TLG, respectively. Mean SUVmax, MTV and TLG of thymic carcinomas were significantly higher compared to thymomas (P<0.01), while no significant differences were observed in the mean quantitative parameters between low-risk and high-risk thymomas.<br />Conclusion: Although SUVmax, MTV and TLG could not distinguish between low-risk and high-risk thymomas, these parameters might be able to differentiate benign tumors from malignant mediastinal tumors noninvasively. These parameters could be used to distinguish between thymomas and thymic carcinomas as well. Therefore, FDG-PET/CT parameters seem to be accurate indices for the detection of malignant mediastinal tumors.Mashhad University of Medical Sciences in collaboration with
AOFNMBAsia Oceania Journal of Nuclear Medicine and Biology2322-57185120170101The Efficiency of Respiratory-gated 18F-FDG PET/CT in Lung Adenocarcinoma: Amplitude-gating Versus Phase-gating Methods3036774710.22038/aojnmb.2016.7747ENYoshiyuki KitamuraDepartment of Clinical Radiology, Kyushu University Hospital, Fukuoka, JapanShingo BabaDepartment of Clinical Radiology, Kyushu University Hospital, Fukuoka, JapanTakuro IsodaDepartment of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JapanYasuhiro MaruokaDepartment of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JapanSatoshi KawanamiDepartment of Molecular Imaging and Diagnosis, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JapanKazuhiko HimuroDivision of Radiology, Department of Medical Technology, Kyushu University Hospital, Fukuoka, JapanMasayuki SasakiDepartment of Health Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan0000-0002-4191-2861Hiroshi HondaDepartment of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JapanJournal Article20160218Objective(s): In positron emission tomography (PET) studies, thoracic movement under free-breathing conditions is a cause of image degradation. Respiratory gating (RG) is commonly used to solve this problem. Two different methods, i.e., phase-gating (PG) and amplitude-gating (AG) PET, are available for respiratory gating. It is important to know the strengths and weaknesses of both methods when selecting an RG method<br />for a given patient. We conducted this study to clarify whether AG or PG is preferable for measuring fluorodeoxyglucose (FDG) accumulation in lung adenocarcinoma and to investigate patient conditions which are most suitable for AG and PG methods.<br />Methods: A total of 31 patients (11 males, 20 females; average age: 11.6±70.1 yrs) with 44 lung lesions, diagnosed as lung adenocarcinoma between April 2012 and March 2013, were investigated. Whole-body FDG-PET/CT scan was performed with both PG and AG methods in all patients. The maximum standardized uptake value (SUVmax) of PG, AG, and the control data of these two methods were measured, and the increase ratio (IR), calculated as IR(%)= (Post – Pre)/Pre × 100, was calculated. The diameter and position<br />of lung lesions were also analyzed. We defined an ‘effective lesion’ of PG (or AG) as a lesion which showed a higher IR compared to AG (or PG). 8 (25.8%)<br />Results: The average SUVmax and average IR were 7.94±8.99 and 25.6±21.4% in PG and 6.70±7.60 and 14.4±4.0% in AG, respectively. Although there was no significant difference between the average SUVmax of PG and AG (P=0.09), the average IR of PG was significantly higher than that of AG (P<0.01). The number of PG- and AG-effective lesions was 32 (72.7%) and 12 (28.3%) , respectively. There was no significant difference in the average diameter or position of the lesions between the PG- and AG-effective lesions.There were 23 (74.2%) PG-effective and 8 (25.8%) AG-effective patients. No significant difference was observed in sex or age between PG- and AG-effective patients.<br />Conclusion: The PG method was more effective for measuring FDG accumulation of lung lesions under free-breathing conditions in comparison with the AG method.Mashhad University of Medical Sciences in collaboration with
AOFNMBAsia Oceania Journal of Nuclear Medicine and Biology2322-57185120170101Uptake index of 123I-metaiodobenzylguanidine myocardial scintigraphy for diagnosing Lewy body disease3743797210.22038/aojnmb.2016.7972ENYoshito KamiyaGraduate School of Health Sciences, Kumamoto University, Kuhonji 4-24-1, Chuo-ku, Kumamoto 862-0796, JapanSatoru OtaGraduate School of Health Sciences, Kumamoto UniversityShintaro OkumiyaGraduate School of Health Sciences, Kumamoto UniversityKosuke YamashitaFujifilm RI Pharma Co.,Ltd.Akihiro TakakiFaculty of Life Sciences, Kumamoto University,Shigeki ItoDepartment of Medical Imaging, Faculty of Life Sciences, Kumamoto University, Kuhonji 4-24-1, Kumamoto 862-0796, Japan0000-0002-8807-7613Journal Article20160828Objective(s): Iodine-123 metaiodobenzylguanidine (123I-MIBG) myocardial scintigraphy has been used to evaluate cardiac sympathetic denervation in Lewy body disease (LBD), including Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). The heart-tomediastinum ratio (H/M) in PD and DLB is significantly lower than that in Parkinson’s plus syndromes and Alzheimer’s disease. Although this ratio is useful for distinguishing LBD from non-LBD, it fluctuates depending on the system performance of the gamma cameras. Therefore, a new, simple quantification method using 123I-MIBG uptake analysis is required for clinical study. The purpose of this study was to develop a new uptake index with a simple protocol to determine 123I-MIBG uptake on planar images.<br />Methods: The 123I-MIBG input function was obtained from the input counts of the pulmonary artery (PA), which were assessed by analyzing the PA time-activity curves. The heart region of interest used for determining the H/M was used for calculating the uptake index, which was obtained by dividing the heart count by the input count.<br />Results: Forty-eight patients underwent 123I-MIBG chest angiography and planar imaging, after clinical feature assessment and tracer injection. The H/M and 123I-MIBG uptake index were calculated and correlated with clinical features. Values for LBD were significantly lower than those for non-LBD in all analyses (P<0.001). The overlapping ranges between non-LBD and LBD were 2.15 to 2.49 in the H/M method, and 1.04 to 1.22% in the uptake index method. The diagnostic accuracy of the uptake index (area under the curve (AUC), 0.98; sensitivity, 96%; specificity, 91%; positive predictive value (PPV), 90%; negative predictive value (NPV), 93%; and accuracy, 92%) was approximately equal to that of the H/M (AUC, 0.95; sensitivity, 93%; specificity, 91%; PPV, 90%; NPV, 93%; and accuracy, 92%) for discriminating patients with LBD and non-LBD.<br />Conclusion: A simple uptake index method was developed using 123I-MIBG planar imaging and the input counts determined by analyzing chest radioisotope angiography images of the PA. The diagnostic accuracy of the uptake index was approximately equal to that of the H/M for discriminating patients with LBD and non-LBD.Mashhad University of Medical Sciences in collaboration with
AOFNMBAsia Oceania Journal of Nuclear Medicine and Biology2322-57185120170101Evaluation of the Efficacy of Standardized Uptake Value (SUV)-shape Scheme for Thyroid Volume Determination in Graves’ Disease: A Comparison with Ultrasonography4448740110.22038/aojnmb.2016.7401ENYangchun ChenNuclear medicine department of Quanzhou First Hospital Affiliated Fujian Medical UniversitySiPei XieUltrasound department of Quanzhou First Hospital Affiliated Fujian Medical UniversityFang HeEndocrine department of Quanzhou First Hospital Affiliated Fujian Medical UniversityJianWei ChenNuclear Medicine department of Quanzhou First Hopital Affiliated Fujian Medical UniversityJournal Article20160126Objective(s): In this study, we aimed to evaluate the efficacy of thyroid volume measurement using 99mTc pertechnetate single-photon emission computed tomography (SPECT) images, acquired by the standardized uptake value (SUV)-shape scheme designed by our expert team.<br />Methods: A total of 18 consecutive patients with Graves’ disease (GD) were subjected to both ultrasonographic and 99mTc pertechnetate SPECT examinations of thyroid within a five-day interval. The volume of thyroid lobes and isthmus was measured by ultrasonography (US) according to the ellipsoid volume equation. The total thyroid volume, determined as the sum of the volume of both lobes and isthmus, was recorded as TV-US (i.e., thyroid volume measured by US) and set as the reference. The thyroid volume was defined according to our SUV-shape scheme and was recorded as TV-SS (i.e., thyroid volume determined by the SUV-shape scheme). The data were analyzed using the Bland-Altman plot, linear regression analysis, Spearman’s rank correlation, and paired t-test, if necessary.<br />Results: The values of TV-SS (40.2±29.4 mL) and TV-US (43.0±34.7 mL) were not significantly different (t=0.813; P=0.43). The linear regression equation of the two values was determined as TV-US= 1.072 × TV-SS − 0.29(r=0.906; P<0.01).<br />Conclusion: The new scheme, i.e., SUV-shape scheme, exhibited potential for the measurement of thyroid volume in patients with GD.Mashhad University of Medical Sciences in collaboration with
AOFNMBAsia Oceania Journal of Nuclear Medicine and Biology2322-57185120170101Influence of the Different Primary Cancers and Different Types of Bone Metastasis on the Lesion-based Artificial Neural Network Value Calculated by a Computer-aided Diagnostic System,BONENAVI, on Bone Scintigraphy Images4955760610.22038/aojnmb.2016.7606ENTAKURO ISODADepartment of Diagnostic Radiology
Sapporo Medical UniversitySINGO BABADepartment of Clinical Radiology
Graduated School of Medical Sciences
Kyushul UniversityYASUHIRO MARUOKADepartment of Clinical Radiology Graduated School of Medical Sciences
Kyushu UniversityYOSHIYUKI KITAMURADepartment of Clinical Radiology
Graduated School of Medical Sciences
Kyushu UniversityKEIICHIRO TAHARADepartment of Clinical Radiology
Graduated School of Medical Sciences
Kyushu UniversityMASAYUKI SASAKIDepartment of Health Sciences
Graduate School of Medical Sciences
Kyushu University0000-0002-4191-2861Masamitsu HatakenakaDepartment of Diagnostic Radiology
Sapporo Medical UniversityHIROSHI HONDADepartment of Clinical Radiology
Graduate School of Medical Sciences
Kyushu UniversityJournal Article20160320Objective(s): BONENAVI, a computer-aided diagnostic system, is used in bone scintigraphy. This system provides the artificial neural network (ANN) and bone scan index (BSI) values. ANN is associated with the possibility of bone metastasis, while BSI is related to the amount of bone metastasis. The degree of uptake on bone scintigraphy can be affected by the type of bone metastasis. Therefore, the ANN value provided by BONENAVI may be influenced by the characteristics of bone metastasis. In this study, we aimed to assess the relationship between ANN value and characteristics of bone metastasis.<br /> Methods: We analyzed 50 patients (36 males, 14 females; age range: 42–87 yrs, median age: 72.5 yrs) with prostate, breast, or lung cancer who had undergone bone scintigraphy and were diagnosed with bone metastasis (32 cases of prostate cancer, nine cases of breast cancer, and nine cases of lung cancer). Those who had received systematic therapy over the past years were excluded. Bone metastases were diagnosed clinically, and the type of bone metastasis (osteoblastic, mildly osteoblastic,osteolytic, and mixed components) was decided visually by the agreement of two radiologists. We compared the ANN values (case-based and lesion-based) among the three primary cancers and four types of bone metastasis.<br />Results: There was no significant difference in case-based ANN values among prostate, breast, and lung cancers. However, the lesion-based ANN values were the highest in cases with prostate cancer and the lowest in cases of lung cancer (median values: prostate cancer, 0.980; breast cancer, 0.909; and lung cancer, 0.864). Mildly osteoblastic lesions showed significantly lower ANN values than the other three types of bone metastasis (median values: osteoblastic, 0.939; mildly osteoblastic, 0.788; mixed type, 0.991; and osteolytic, 0.969). The possibility of a lesion-based ANN value below 0.5 was 10.9% for bone metastasis in prostate cancer, 12.9% for breast cancer, and 37.2% for lung cancer. The corresponding possibility were 14.7% for osteoblastic metastases, 23.9% for mildly osteoblastic metastases, 7.14% for mixedtype metastases, and 16.0% for osteolytic metastases.<br />Conclusion: The lesion-based ANN values calculated by BONENAVI can be influenced by the type of primary cancer and bone metastasis.Mashhad University of Medical Sciences in collaboration with
AOFNMBAsia Oceania Journal of Nuclear Medicine and Biology2322-57185120170101Salivary Gland Scintigraphy in Patients with Sjogren’s Syndrome: A local Experience with Dual-tracer5665802910.22038/aojnmb.2016.8029ENWing Hang LukPrincess Margaret Hospital, Hong KongJessie Tse Hang YeungPrincess Margaret HospitalEliza Po Yan FungKwong Wah HospitalChiu Ming LokBaptist HospitalYuet Ming NgHong Kong Education UniversityJournal Article20160712Objective(s): To review the findings of the patients with Sjögren’s syndrome (SS) having technetium-99m-pertechnetate (99mTc-pertechnetate) and gallium-67 citrate (Ga-67) salivary gland scintigraphy in the past eight years.<br />Methods: The patients with SS, who were referred to our department for salivary gland scintigraphy during January 2008-December 2015 were studied using both 99mTc-pertechnetate and Ga-67 citrate scintigraphy.<br />Results: Eighteen patients were included in the study, 17 of whom had positive findings on 99mTc- pertechnetate salivary gland scintigraphy. One patient had negative parotid glands findings on 99mTc-pertechnetate, but positive findings in Ga-67 study. Four patients had asymmetric involvement of the parotid glands, and one patient had asymmetric involvement of the submandibular glands in 99mTc-pertechnetate salivary gland scintigraphy. On the other hand, one patient had only submandibular gland involvement in the 99mTc-pertechnetate scan.Nine patients (9/18) had positive parotid gland findings on Ga-67 study. The involvements of the parotid glands were all symmetrical, except for one patient. No abnormal gallium uptake in the submandibular glands in our patients was noted.<br />Conclusion: 99mTc-pertechnetate salivary gland scintigraphy is sufficient for the assessment in the majority of patients with SS. Ga-67 scintigraphy may be a useful supplementary test, especially if the result of 99mTc-pertechnetate scintigraphy is not conclusive.Mashhad University of Medical Sciences in collaboration with
AOFNMBAsia Oceania Journal of Nuclear Medicine and Biology2322-57185120170101Changing Therapeutic Paradigms: Predicting mCRC Lesion Response to Selective Internal Radionuclide Therapy (SIRT) based on Critical Absorbed Dose Thresholds: A Case Study6669789210.22038/aojnmb.2016.7892ENKathy WInstitute of Medical Physics, The University of Sydney0000-0002-2195-0596Elizabeth BernardThe department fo Nuclear Medicine, Royal North Shore HospitalRichard MaherDepartment of Radiology, Royal North Shore HospitalStephen ClarkeDepartment of Medical Oncology, Royal North Shore HospitalDale BaileyDepartment of Nuclear Medicine, Royal North Shore Hospital
Faculty of Health Sciences, The University of Sydney0000-0001-9154-7957Journal Article20160823A 65 year old male with metastatic colorectal cancer (mCRC) in the liver was referred for selective internal radionuclide therapy (SIRT) following a history of extensive systemic chemotherapy. 90Y PET imaging was performed immediately after treatment and used to confirm lesion targeting and measure individual lesion absorbed doses. Lesion dosimetry was highly predictive of eventual response in the follow-up FDG PET performed 8 weeks after therapy. The derived radiation dose map was used to plan a second SIRT procedure aiming to protect healthy liver by keeping absorbed dose below the critical dose threshold, whilst targeting the remaining lesions that had received sub-critical dosing. Again, 90Y PET was performed immediately post-treatment and used to derive absorbed dose measures to both lesions and healthy parenchyma. Additional followup FDG PET imaging again confirmed the role of the 90Y PET dose map as an early predictor of response, and a tool for safe repeat treatment planning.Mashhad University of Medical Sciences in collaboration with
AOFNMBAsia Oceania Journal of Nuclear Medicine and Biology2322-5718512017010118F-FDG PET/CT in pleural epithelioid hemangioendothelioma7074797110.22038/aojnmb.2016.7971ENDomenico AlbanoSpedali Civili BresciaGiovanni BosioNuclear Medicine, University of Brescia and Spedali Civili Brescia, Brescia, Italy.Andrea TironiDepartment of Molecular and Translational Medicine, Anatomic Pathology Section, Spedali Civili Brescia, Brescia, Italy.Francesco BertagnaNuclear Medicine, University of Brescia and Spedali Civili Brescia, Brescia, Italy.Journal Article20160823Pleural epithelioid hemangioendothelioma (EHE) is a rare malignancy of vascular-endothelial origin with non-specific symptoms and an unpredictable outcome. Diagnosis of this condition by imaging modalities is challenging, and no standard therapeutic approaches have been established in this regard. In this paper, we described the case of a patient with a low-grade fever, coughing and chest pain who underwent 18F-FDG PET/CT after a positive thorax CT showing multiple bilateral calcified pulmonary nodules and extensive right-sided pleural effusion. Moreover, PET/CT revealed increased tracer uptake on the nodular pleural thickening and one nodule in the upper lobe of the right lung. A diagnostic thoracentesis was performed to obtain the pleural fluid. However, cytology was not diagnostic, and the subsequent thoracotomy with pleural fluid drainage and pleural biopsy was positive for pleural EHE. The study showed also an abundant non-FDG-avid pleural effusion in the collapsed right lung. Despite chest tube insertion and partial drainage of the volume, patient’s condition deteriorated, and patient passed away six months after the PET scan.